Brian S. Levitt
Research Subjects
Research Interests
Brian S. Levitt has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Huy N. Trinh
Pacific Health Foundation
17 shared publications - Huy A. Nguyen
San Jose Gastroenterology
16 shared publications - Khanh K. Nguyen
San Jose Gastroenterology
16 shared publications Ruel T. Garcia
14 shared publications- Mindie H. Nguyen
Division of Gastroenterology and Hepatology Department of Medicine Stanford University Medical Center Palo Alto California USA
13 shared publications - Kevin T. Chaung
Pacific Health Foundation
5 shared publications
Latest Publications
- 1 October 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (11) , 3342-3347
Less-Established Risk Factors Are Common in Asian Americans with Hepatitis C Virus: A Case–Controlled Study
- 1 October 2013
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 58 (11) , 3342-3347
Less-Established Risk Factors Are Common in Asian Americans with Hepatitis C Virus: A Case–Controlled Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1043 Outcomes of Oral Antiviral Treatment for Chronic Hepatitis B (CHB) in Routine Clinical Practice
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1043 Outcomes of Oral Antiviral Treatment for Chronic Hepatitis B (CHB) in Routine Clinical Practice
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1087 Less Established Risk Factors are Common in Asian Americans With Hepatitis C Virus: A Case-Control Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1087 Less Established Risk Factors are Common in Asian Americans With Hepatitis C Virus: A Case-Control Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1003 High Prevalence of Hepatitis C Virus in Ethnically Diverse Community Patients With Non-Liver Related Gastrointestinal Complaints
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1003 High Prevalence of Hepatitis C Virus in Ethnically Diverse Community Patients With Non-Liver Related Gastrointestinal Complaints
- 17 February 2011
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 56 (8) , 2423-2431
Medication Nonadherence with Long-Term Management of Patients with Hepatitis B e antigen-Negative Chronic Hepatitis B
Antiviral treatment responses for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) are well-defined by data from registration trials but may differ from patients seen in community settings where medical adherence is usually not as strictly monitored. The goal of this study was to examine the long-term outcomes of HBeAg-negative patients in a community clinical setting. We performed a cohort study of 189 consecutive treatment-naïve patients with CHB who were treated with either entecavir (ETV) 0.5 mg daily (n = 107) or adefovir dipivoxil (ADV) 10 mg daily (n = 82) from 2002 to 2009 at two community clinics. All patients were Asians. Both ETV and ADV cohorts had similar median baseline ALT and HBV DNA levels. By year 4, a similar proportion of ETV and ADV patients who remained on monotherapy achieved complete viral suppression (91–96%); however, more patients in the ADV cohort required alternative therapy (27 vs. 5%). No patients in the ETV cohort developed resistance while 18% of the ADV cohort did. Cumulative nonadherence rates were 10 and 12% in ADV and ETV cohorts, respectively. Failure to monotherapy in a community clinical setting is due to both antiviral resistance and patient nonadherence. Medication nonadherence is likely to be a more important contributor to treatment failure than antiviral resistance, especially with new anti-HBV agents such as ETV and tenofovir.
- 17 February 2011
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 56 (8) , 2423-2431
Medication Nonadherence with Long-Term Management of Patients with Hepatitis B e antigen-Negative Chronic Hepatitis B
Antiviral treatment responses for patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) are well-defined by data from registration trials but may differ from patients seen in community settings where medical adherence is usually not as strictly monitored. The goal of this study was to examine the long-term outcomes of HBeAg-negative patients in a community clinical setting. We performed a cohort study of 189 consecutive treatment-naïve patients with CHB who were treated with either entecavir (ETV) 0.5 mg daily (n = 107) or adefovir dipivoxil (ADV) 10 mg daily (n = 82) from 2002 to 2009 at two community clinics. All patients were Asians. Both ETV and ADV cohorts had similar median baseline ALT and HBV DNA levels. By year 4, a similar proportion of ETV and ADV patients who remained on monotherapy achieved complete viral suppression (91–96%); however, more patients in the ADV cohort required alternative therapy (27 vs. 5%). No patients in the ETV cohort developed resistance while 18% of the ADV cohort did. Cumulative nonadherence rates were 10 and 12% in ADV and ETV cohorts, respectively. Failure to monotherapy in a community clinical setting is due to both antiviral resistance and patient nonadherence. Medication nonadherence is likely to be a more important contributor to treatment failure than antiviral resistance, especially with new anti-HBV agents such as ETV and tenofovir.
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
M1892 Hepatitis B-E Antigen Positive (HBeAg+) Chronic Hepatitis B (CHB) Patients With Precore (PC) and Basic Core Promoter (BCP) Mutations
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
M1892 Hepatitis B-E Antigen Positive (HBeAg+) Chronic Hepatitis B (CHB) Patients With Precore (PC) and Basic Core Promoter (BCP) Mutations